Progenics and Ono to Codevelop Relistor in Japan « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
October 2008

M T W T F S S

« Sep Nov »

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

Progenics and Ono to Codevelop Relistor in Japan

Posted on October 22, 2008 by crimsoncanary

Ono have signed an agreement to license Relistor (methylnaltrexone bromide) from Progenics for development in Japan

Filed under: Uncategorized | Tagged: Licensing, Methylnaltrexone, ono, Opioid, progenics

« ChemoCentryx initiate Phase I trial of CCR9 antagonist CCX025 NeurogesX Submit NDA for NGX-4010 for Treatment of Postherpetic Neuralgia (PHN) »